Insilico Medicine & Servier Strike a $888 Mn Deal to Boost Oncology Drug Discovery

The company will use its proprietary Pharma.AI platform to identify and advance potential drug candidates during the early stages of discovery.

Hong Kong-based Insilico Medicine, a biotechnology company focused on artificial intelligence-driven drug discovery, has announced a multi-year research and development collaboration with French pharmaceutical group Servier.

As per reports, the agreement is valued at up to $888 million.

The new partnership aims to boost the discovery and development of potential oncology therapies using artificial intelligence–based technologies.

Under the agreement, Insilico will receive up to $32 million in upfront and near-term R&D payments.

The company will use its proprietary Pharma.AI platform to identify and advance potential drug candidates during the early stages of discovery.

Servier is expected to share research and development costs and, if promising candidates are identified, to assume responsibility for subsequent clinical validation, regulatory engagement, and global commercialization.

The partnership brings together Insilico’s AI-based discovery technology with Servier’s experience in cancer drug development.

Insilico has previously developed a pipeline of oncology programs, including early-stage assets such as the pan-TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412, both of which are in global Phase I clinical trials.

Insilico has an existing pipeline of oncology programmes and clinical trials.

Further, the company has also out-licensed several additional programmes to partners.

Commenting on the partnership, Alex Zhavoronkov, founder, CEO and CBO of Insilico Medicine said, "As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development."

Recently, the biotech company had also entered into a research and licensing collaboration with U.S. drugmaker Eli Lilly, valued at over $100 million, to advance AI-driven drug discovery under which Insilico is expected to use its generative AI platform to generate, design, and optimise novel compounds for targets jointly defined by Lilly.

The new agreement follows Insilico’s recent listing on the Hong Kong Stock Exchange in late December 2025.

Stay tuned for more such updates on Digital Health News